WCMNY
GILD icon

Westchester Capital Management (New York)’s Gilead Sciences GILD Stock Holding History

Westchester Capital Management (New York)’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-44,500
Closed -$3.69M – 154
2014
Q2 		$3.69M Hold
44,500
– – 0.05% 126
2014
Q1 		$3.15M Buy
+44,500
New +$3.49M 0.04% 127

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Westchester Capital Management (New York)'s GILD Position: Q3 2014 in Review

Westchester Capital Management (New York) sold out of Gilead Sciences (GILD) in Q3 2014, closing a stake of 44,500 shares — an estimated $3.69M sold.

Westchester Capital Management (New York) first reported a position in GILD in Q1 2014 and held it in 2 quarters. The position peaked at $3.69M in Q2 2014. 1,327 funds tracked by Wall St. Rank hold GILD as of Q3 2014.

  • Westchester Capital Management (New York) reported no remaining Gilead Sciences position as of Q3 2014 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 44,500 Gilead Sciences shares in Q3 2014, an estimated $3.69M.
  • Westchester Capital Management (New York) first reported a position in Gilead Sciences in Q1 2014 and held it in 2 quarters.
  • Westchester Capital Management (New York)'s Gilead Sciences position peaked at $3.69M in Q2 2014.
  • 1,327 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2014.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2014, filed 14 Nov 2014.